With 57.78 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.27 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $1.26 whereas the lowest price it dropped to was $0.925. The 52-week range on GELS shows that it touched its highest point at $5.50 and its lowest point at $0.77 during that stretch. Beta for the stock currently stands at -0.13.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GELS was up-trending over the past week, with a rise of 12.74%, but this was down by -14.52% over a month. Three-month performance dropped to -17.19% while six-month performance fell -41.11%. The stock lost -54.31% in the past year, while it has lost -29.80% so far this year.
Float and Shares Shorts:
At present, 9.44 million GELS shares are outstanding with a float of 3.74 million shares on hand for trading. On 2025-10-31, short shares totaled 7382.0, which was 6.999999999999999 higher than short shares on 1759190400. In addition to Mr. Nathan Jacob Givoni as the firm’s Co-Founder, CEO & Executive Director, Mr. Simon Hayden Szewach serves as its Co-Founder & Non-Executive Chairman.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, GELS reported revenue of $0.0 and operating income of -$911620.0.
